Skip to content

Cobra Biologics and Recopharma Enter agreement to utilise Cobra’s Cell Line Development Service- MaxXpress

The service allows Recopharma to form a quick and reliable assessment on the specific expertise of Cobra’s cell line development and analytical scientist teams.

Recopharma has developed a unique technology that uses mucins, naturally occurring proteins produced by epithelial tissues with many potential applications. The FC fused mucins will provide a natural alternative to ocular lubricants and tear substitutes that are at present available and set to be used as a treatment and prophylactic that tackles viral conjunctivitis.

Peter Coleman CEO of Cobra Biologics commented: “I am very pleased that Recopharma has chosen Cobra to supply pre-clinical material. Cobra’s MaxXpress service has proven very popular with customers. Indeed, the service allows customers to make a fast assessment as to whether the UCOE technology and cell development team are the best combination to take their protein forward to clinical trials”.

Jan Holgersson, CEO/ CSO of Recopharma said “We are very excited about working with Cobra Biologics, and to apply their cell line development expertise on our mucin-type fusion proteins. A cell pool providing good yields will be an important commercial milestone on our path towards clinical studies with our dry eye disease lead compound.”

This website uses cookies. For more information about these please click here.
By continuing to browse you consent to the use of cookies